Literature DB >> 34035688

Ivabradine Monotherapy for the Treatment of Congenital Junctional Ectopic Tachycardia in a Premature Neonate.

Suzan S Asfour, Khalid A Al-Omran, Nabeel A Alodhaidan, Raneem S Asfour, Thanaa M Khalil, Mountasser M Al-Mouqdad.   

Abstract

Congenital junctional ectopic tachycardia is a rare and special type of supraventricular arrhythmia. Junctional ectopic tachycardia is characterized by persistently elevated heart rates that may cause an impairment in cardiac function. Junctional ectopic tachycardia is considered one of the most difficult-to-treat conditions even with a combination of antiarrhythmic medications. Ivabradine is a novel antiarrhythmic medication used to decrease the heart rate in adults with angina pectoris. We report a first case of a premature neonate with a normal heart structure who developed junctional ectopic tachycardia and was subsequently treated successfully with ivabradine. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.

Entities:  

Keywords:  case report; congenital; ivabradine; junctional ectopic tachycardia; premature neonate

Year:  2021        PMID: 34035688      PMCID: PMC8139562          DOI: 10.5863/1551-6776-26.4.414

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  13 in total

Review 1.  Impact of developmental pharmacology on pediatric study design: overcoming the challenges.

Authors:  G L Kearns
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

2.  Junctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome.

Authors:  Leena Mildh; Anita Hiippala; Paula Rautiainen; Ville Pettilä; Heikki Sairanen; Juha-Matti Happonen
Journal:  Eur J Cardiothorac Surg       Date:  2011-01       Impact factor: 4.191

3.  Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: Case studies.

Authors:  Yakup Ergul; Erkut Ozturk; Senem Ozgur; Abdullah Ozyurt; Erman Cilsal; Alper Guzeltas
Journal:  Pacing Clin Electrophysiol       Date:  2018-06-27       Impact factor: 1.976

4.  Junctional ectopic tachycardia in children: electrocardiography, electrophysiology and pharmacologic response.

Authors:  A Garson; P C Gillette
Journal:  Am J Cardiol       Date:  1979-08       Impact factor: 2.778

Review 5.  Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study.

Authors:  E Villain; V L Vetter; J M Garcia; J Herre; A Cifarelli; A Garson
Journal:  Circulation       Date:  1990-05       Impact factor: 29.690

6.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

7.  Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia.

Authors:  Saleh Al-Ghamdi; Majid I Al-Fayyadh; Robert M Hamilton
Journal:  J Cardiovasc Electrophysiol       Date:  2013-02-01

8.  Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia.

Authors:  Jana-Katharina Dieks; Sophia Klehs; Matthias J Müller; Thomas Paul; Ulrich Krause
Journal:  Heart Rhythm       Date:  2016-06       Impact factor: 6.343

9.  Ivabradine for treatment of tachyarrhythmias in children and young adults.

Authors:  Christopher M Janson; Reina Bianca Tan; V Ramesh Iyer; R Lee Vogel; Victoria L Vetter; Maully J Shah
Journal:  HeartRhythm Case Rep       Date:  2019-03-26

Review 10.  Ivabradine, coronary artery disease, and heart failure: beyond rhythm control.

Authors:  Pietro Scicchitano; Francesca Cortese; Gabriella Ricci; Santa Carbonara; Michele Moncelli; Massimo Iacoviello; Annagrazia Cecere; Michele Gesualdo; Annapaola Zito; Pasquale Caldarola; Domenico Scrutinio; Rocco Lagioia; Graziano Riccioni; Marco Matteo Ciccone
Journal:  Drug Des Devel Ther       Date:  2014-06-03       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.